Brazil’s health regulator authorizes Butantan to conduct human trials for anti-Covid serum

On March 24, the agency had approved the research, but conditioned to the signing of a term of commitment that provided for the delivery of additional data, which were then submitted. With the decision, the Butantan Institute may begin to test the serum on trial volunteers.

RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) on Tuesday, May 25, authorized the start of trials of the anti-Sars-CoV-2 serum, developed by the Butantan Institute, in São Paulo.

With the decision, the Butantan Institute may begin to test the serum on trial volunteers. This will be the first time that the serum will be tested in humans.

On March 24, the agency had approved the research, but conditioned to the signing of a term of commitment that provided for the delivery of additional data, which were not available at that time.

Yesterday's . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?